Kisunla

FDA Approval for Revolutionary Alzheimer’s Drug – Kisunla Clears Way for Breakthrough Treatment

by

Indianapolis, Indiana – The Food and Drug Administration gave the green light on Tuesday to a new Alzheimer’s treatment called donanemab, marking the third addition to a novel class of drugs designed to slow the brain’s decline in patients grappling with the early stages of the disease. Named Kisunla by Eli Lilly, the drug’s approval comes after facing numerous setbacks and delays in bringing the experimental treatment to the market, despite promising results from clinical …

Read more

Breakthrough: FDA Approves Alzheimer’s Drug Kisunla for Slowing Disease Progression

by

INDIANAPOLIS, Ind. – The Food and Drug Administration granted approval on Tuesday to a highly anticipated Alzheimer’s drug called Kisunla, manufactured by Eli Lilly. This approval comes after a delay in March to further assess the drug’s safety and effectiveness. The drug was greenlit by the FDA following a panel of independent experts unanimously endorsing it in May. Kisunla, the brand name for donanemab, is one of the few Alzheimer’s treatments that actually modifies the …

Read more